(Q36292157)

13 August 2017

The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study (English)

1 reference

13 August 2017

1 reference

1 reference

Singer JM

1

1 reference

13 August 2017

Hartley JM

2

1 reference

13 August 2017

Brennan C

3

1 reference

13 August 2017

Nicholson PW

4

1 reference

13 August 2017

Souhami RL

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

978-984

1 reference

13 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.161

13 August 2017

0 references

cites work

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

The analysis of ifosfamide and its metabolites (review).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Metabolism of ifosfamide during a 3 day infusion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Ifosfamide clinical pharmacokinetics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Ifosfamide metabolism and pharmacokinetics (review).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Ifosfamide--pharmacology, safety and therapeutic potential

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Reduction of ifosfamide toxicity using dose fractionation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Pharmacokinetics of divided‐dose ifosfamide

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Human pharmacokinetic model for isophosphamide (NSC-1097241)

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150089

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

22 September 2018

1 reference

12 December 2020

Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma

1 reference

12 December 2020

The oxazaphosphorines

1 reference

12 December 2020

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration

1 reference

12 December 2020

The effect of route of administration and fractionation of dose on the metabolism of ifosfamide

1 reference

12 December 2020

Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557)

1 reference

12 December 2020

Clinical pharmacology of isophosphamide

1 reference

12 December 2020

Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes

1 reference

12 December 2020

In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes

1 reference

12 December 2020

Comparison of continuous infusion and bolus administration of ifosfamide in children

1 reference

12 December 2020

Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma

1 reference

12 December 2020

Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat

1 reference

12 December 2020

Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children

1 reference

12 December 2020

Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro

1 reference

12 December 2020

Cyclophosphamide metabolism in children

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.161

1 reference

13 August 2017

1 reference

13 August 2017

1 reference